Smart-Money SignalNeutral · 49/100— Insiders are net sellers over 90 days (-$20K, 4 sales vs 0 buys)
Net Income-$8.8M
EPS$0.04
Market Cap$460.6M
Price Performance
Historical data including institutional events
Company Profile
A
Adi George
CEO & Executive Director
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States.
Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc).
Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv-Yafo, Israel.
